New Survey Suggests Biologics Could Be the New Vanguard For Treating Crohn’s Disease, Ulcerative Colitis

New Survey Suggests Biologics Could Be the New Vanguard For Treating Crohn’s Disease, Ulcerative Colitis
In their latest report, entitled, “Crohn’s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars,” Decision Resources, a Decision Resources Group company, surveyed gastroenterologists and payers about the current use of biologics and their perception on the future role of biosimilar versions in patients' treatments. Biologics constitute the newest treatment for Crohn’s Disease (CD) and Ulcerative Colitis (UC). Unlike corticosteroids, which suppress the entire immune system, biologics have specific antibodies binding selectively to CD triggering factors. Biologic treatments for CD and UC include TNF inhibitors and Integrin receptor antagonists. The report focused on the available TNF inhibitors for CD, REMICADE® (infliximab), HUMIRA® (adalimumab), SIMPONI® (golimumab) and UCB’s CIMZIA® (certolizumab pegol); anti-integrins TYSABRI® (natalizumab) and ENTYVIO (Vedolizumab); new therapies include STELARA® (ustekinumab) and XELJANZ® (tofacitinibcitrate); and the new biosimilars for REMICADE® (infliximab) and HUMIRA® (adalimumab). The key findings from the report were: Current treatment for CD and UC: gastroenterologists reported that among those in the CD/UC patient population who can actually receive a biologic, approximately 20 percent reported treatment failure and ultimately discontinued it; these patients are thus eager to try new treatments with a different mode of action. Emerging therapies in CD and UC: Emerging therapies are likely to have a favorable outlook. However, to be able to be implemented with efficacy, managed care organizations (MCOs) highlight the need for cost incentives (such as, lower list price and the possibility of
Subscribe or to access all post and page content.